Clinical Trial Update: An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating enzalutamide plus androgen deprivation therapy versus placebo plus ADT in Chinese men with metastatic hormone-sensitive prostate cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Astellas Pharma China, Inc. | Conditions: Metastatic Hormone Sensitive Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-18